ArticleInternational journal of clinical and experimental medicine2015
APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- APC gene promoter methylation as a potential biomarker for lung cancer diagnosis: A meta-analysis.Thoracic cancer · 2021Pooled it
- Association of APC gene promoter methylation and the risk of gastric cancer: A meta-analysis and bioinformatics study.Medicine · 2020Pooled it
- Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.Nature communications · 2026Article
- Review
- Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.The Prostate · 2018Article
- Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The promoter region of adenomatous polyposis coli (APC) has been found to be frequently methylated in prostate cancer. However, the prognostic role of APC methylation in prostate cancer was still debated. We performed a meta-analysis by searching PubMed and EMBASE databases. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were calculated. Seven studies (1227 patients) were included in this study. After calculation, the overall HR was 1.74 (95% CI: 1.31-2.31), implicating that APC methylation has an unfavorable impact on biochemical recurrence of prostate cancer. A subgroup analysis was performed with detection method, combined HR was 1.53 (95% CI: 1.19-1.96) for Methylation-Specific PCR (MSP), and 2.08 (95% CI: 1.18-3.64) for quantitative Methylation-Specific PCR (qMSP). Another subgroup analysis was conducted according to regions of the patients, combined HR was 2.02 (95% CI: 1.18-3.49) for North America, and 1.64 (95% CI: 1.14-2.36) for European. In conclusion, APC methylation is associated with biochemical recurrence of patients with prostate cancer.
Indexed as
Identifiers
26629051PMC4658940W2188533427What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.